Key terms

About CTLT

Catalent, Inc. is a holding company, which engages in the provision of delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products. It operates through the following segments: Softgel and Oral Technologies, Biologics, Oral and Specialty Delivery, and Clinical Supply Services. The Softgel and Oral Technologies segment offers formulation, development, and manufacturing services for soft capsules or softgels, as well as large-scale production of oral solid dose forms for pharmaceutical and consumer health markets and supporting ancillary services. The Biologics segment develops and produces biologic cell-line, cell therapy, and viral vector gene therapy, formulation for parenteral dose forms, which include prefilled syringes, vials, and cartridges, and analytical development and testing services for large molecules. The Oral and Specialty Delivery segment is composed of advanced formulation of a range of technologies along with integrated downstream clinical development and commercial supply solutions. The Clinical Supply Services segment is involved in packaging, storage, distribution, and inventory management of drugs and biologics in clinical trials. The company was founded in 1933 and is headquartered in Somerset, NJ.

Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
     
52-week range
     
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date

Key terms

Smart score

Latest CTLT news

Today 2:02am ET Catalent’s Merger Deal with Novo Holdings: A Tightrope Walk Amidst Restrictive Clauses and Hefty Termination Fees Today 1:41am ET Catalent’s Resilient Growth and Positive Outlook Reinforce Buy Rating Yesterday 6:49am ET RBC Capital Sticks to Their Hold Rating for Catalent (CTLT) May 08 4:52pm ET Catalent reports Q3 EPS (6c), consensus 21c Apr 12 1:41am ET Analysts Offer Insights on Healthcare Companies: Catalent (CTLT), Vertex Pharmaceuticals (VRTX) and Alkermes (ALKS) Apr 05 3:50am ET Analysts Have Conflicting Sentiments on These Healthcare Companies: Catalent (CTLT), Alvotech (ALVO) and Immunocore Holdings (IMCR) Mar 15 4:55am ET Piper Sandler healthcare/pharma analysts hold analyst/industry conference call Mar 12 5:00pm ET Piper Sandler healthcare/pharma analysts hold analyst/industry conference call Mar 07 1:49pm ET William Blair healthcare analysts hold analyst/industry conference call Mar 05 1:23am ET Analysts Offer Insights on Healthcare Companies: Arbutus Biopharma (ABUS), Twist Bioscience (TWST) and Catalent (CTLT) Feb 20 7:31am ET Analysts Offer Insights on Healthcare Companies: Exact Sciences (EXAS), Alnylam Pharma (ALNY) and Catalent (CTLT) Feb 15 1:00am ET A New Cause for Concern: Catalent Inc Adds a New Share Price & Shareholder Rights Risk Feb 12 5:24pm ET Catalent to delay 10-Q filing Feb 12 8:20am ET Analysts Offer Insights on Healthcare Companies: Exelixis (EXEL), BeiGene (BGNE) and Catalent (CTLT) Feb 12 6:27am ET Catalent price target raised to $63.50 from $56 at Baird Feb 12 3:46am ET Catalent (CTLT) Gets a Hold from Barclays Feb 09 8:08am ET Catalent reports Q2 EPS (24c), consensus (2c) Feb 09 7:05am ET Options Volatility and Implied Earnings Moves Today, February 09, 2024

No recent press releases are available for CTLT

CTLT Financials

1-year income & revenue

Key terms

CTLT Forecasts

analyst rating

  • buy
  • hold
  • sell

We're sorry, but this
information is
temporarily unavailable.

1-year stock price forecast

CTLT Competitors

$ Market cap P/E ratio $ Price 1d change 52-week range

Key terms